DK3538542T3 - Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin - Google Patents

Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin Download PDF

Info

Publication number
DK3538542T3
DK3538542T3 DK17870529.9T DK17870529T DK3538542T3 DK 3538542 T3 DK3538542 T3 DK 3538542T3 DK 17870529 T DK17870529 T DK 17870529T DK 3538542 T3 DK3538542 T3 DK 3538542T3
Authority
DK
Denmark
Prior art keywords
peptime
multimizes
4beta
alfa
integrin
Prior art date
Application number
DK17870529.9T
Other languages
Danish (da)
English (en)
Inventor
Monzur M Morshed
Sai Kumar Chakka
Jennifer L Hickey
Manuel Perez Vazquez
Andrew Roughton
Adam Paul Kafal
Narendrakumar B Patel
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Application granted granted Critical
Publication of DK3538542T3 publication Critical patent/DK3538542T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK17870529.9T 2016-11-11 2017-11-10 Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin DK3538542T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662421117P 2016-11-11 2016-11-11
PCT/CA2017/000244 WO2018085921A1 (en) 2016-11-11 2017-11-10 CYCLIC PEPTIDES MULTIMERS TARGETING α4β7 INTEGRIN

Publications (1)

Publication Number Publication Date
DK3538542T3 true DK3538542T3 (da) 2021-10-11

Family

ID=62110102

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17870529.9T DK3538542T3 (da) 2016-11-11 2017-11-10 Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin

Country Status (8)

Country Link
US (3) US11111273B2 (https=)
EP (2) EP3939989A1 (https=)
JP (2) JP7035044B2 (https=)
CN (1) CN110088121A (https=)
CA (1) CA3042576A1 (https=)
DK (1) DK3538542T3 (https=)
ES (1) ES2884107T3 (https=)
WO (1) WO2018085921A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111273B2 (en) 2016-11-11 2021-09-07 Zealand Pharma A/S Cyclic peptides multimers targeting alpha-4-beta-7 integrin
KR20230079464A (ko) 2017-05-10 2023-06-07 질랜드 파마 에이/에스 α4β7 인테그린을 타겟팅하는 호모데틱 사이클릭 펩타이드
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US20230117920A1 (en) * 2019-12-27 2023-04-20 The University Of Tokyo Library Construction Method, Cyclic Peptide, FXIIa Binder and IFNGR1 Binder
JP2021106565A (ja) * 2019-12-27 2021-07-29 国立大学法人 東京大学 ライブラリーの製造方法、環状ペプチド、ＦＸＩＩａ結合剤、及びＩＦＮＧＲ１結合剤
EP4172177A1 (en) * 2020-06-29 2023-05-03 Zealand Pharma A/S Compounds targeting alpha4-beta7 integrin
US11957761B2 (en) 2021-12-20 2024-04-16 Zealand Pharma A/S Compounds having α4β7 integrin inhibition activity

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3219113A1 (de) 1982-05-21 1983-11-24 Bayer Ag, 5090 Leverkusen Verwendung von n-substituierten 2,3-diaminocarbonsaeuren in arzneimitteln und ihre herstellung
ZA906188B (en) 1989-08-10 1991-06-26 Merrell Dow Pharma Cyclic neurokinin a antagonists
US5296604A (en) 1992-05-15 1994-03-22 Miles Inc. Proline derivatives and compositions for their use as inhibitors of HIV protease
US5705481A (en) 1992-11-06 1998-01-06 Merck Patent Gesellschaft Mit Beschrankter Haftung Cyclopeptides
IL109615A (en) 1993-05-17 2000-12-06 Fujisawa Pharmaceutical Co Cyclic polypeptide derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
US5693325A (en) 1994-03-15 1997-12-02 Molecumetics, Ltd. Peptide vaccines and methods relating thereto
DE4415310A1 (de) 1994-04-30 1995-11-02 Merck Patent Gmbh Cyclopeptide
WO1996000581A1 (en) 1994-06-29 1996-01-11 Texas Biotechnology Corporation Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
AU6311996A (en) 1995-07-06 1997-02-05 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
US5696084A (en) 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
US6492553B1 (en) 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
DE10107707A1 (de) 2001-02-19 2002-08-29 Wilex Biotechnology Gmbh Antagonisten für alpha¶4¶beta¶7¶-Integrin
US6667407B2 (en) 2002-05-03 2003-12-23 Bayer Polymers Llc Process of making polyaziridines
WO2005105827A2 (en) 2004-04-15 2005-11-10 Proteolix, Inc. Compounds for proteasome enzyme inhibition
US8143375B2 (en) 2006-10-20 2012-03-27 The Governing Council Of The University Of Toronto Aziridine aldehydes, aziridine-conjugated amino derivatives, aziridine-conjugated biomolecules and processes for their preparation
EP1961759A1 (en) 2007-02-21 2008-08-27 Universita'degli Studi Di Milano Integrin targeted cyclopeptide ligands, their preparation and use
EP2291390B1 (en) 2008-05-22 2014-11-05 Centre National de la Recherche Scientifique (CNRS) New optically pure compounds for improved therapeutic efficiency
AU2010225426B2 (en) * 2009-03-16 2015-09-03 The Governing Council Of The University Of Toronto Cyclic amino acid molecules and methods of preparing the same
US20120045393A1 (en) 2009-03-17 2012-02-23 Linder Karen E Lhrh-ii peptide analogs
EP2556060A1 (en) 2010-04-08 2013-02-13 Ah Usa 42 Llc Substituted 3,5- diphenyl-isoxazoline derivatives as insecticides and acaricides
WO2012113803A1 (en) 2011-02-22 2012-08-30 Leo Pharma A/S A cyclic peptide and conjugate thereof for binding to keratinocytes
BR112014016736A8 (pt) * 2012-01-27 2017-07-04 Hoffmann La Roche composto, composição farmacêutica, método para tratamento, uso de um composto e invenção
JP6152093B2 (ja) * 2012-04-24 2017-06-21 Ｅａファーマ株式会社 スルホンアミド誘導体及びその医薬用途
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
PT3143037T (pt) 2014-05-16 2021-09-24 Protagonist Therapeutics Inc Antagonistas peptídicos tioéter de integrina alfa4beta7
KR20170108936A (ko) * 2014-10-01 2017-09-27 프로타고니스트 테라퓨틱스, 인코포레이티드 신규한 α4β7 펩타이드 단량체 및 이량체 길항제
EP3201217A4 (en) * 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
US11046695B2 (en) 2015-11-11 2021-06-29 Zealand Pharma A/S Fragment synthesis of substituted cyclic peptides
US11111273B2 (en) * 2016-11-11 2021-09-07 Zealand Pharma A/S Cyclic peptides multimers targeting alpha-4-beta-7 integrin

Also Published As

Publication number Publication date
ES2884107T3 (es) 2021-12-10
JP2020504080A (ja) 2020-02-06
CN110088121A (zh) 2019-08-02
EP3538542A4 (en) 2020-08-26
CA3042576A1 (en) 2018-05-17
JP2022078188A (ja) 2022-05-24
US11713338B2 (en) 2023-08-01
US20200216501A1 (en) 2020-07-09
JP7429726B2 (ja) 2024-02-08
US11111273B2 (en) 2021-09-07
EP3939989A1 (en) 2022-01-19
EP3538542A1 (en) 2019-09-18
WO2018085921A1 (en) 2018-05-17
US20230406884A1 (en) 2023-12-21
US12077611B2 (en) 2024-09-03
US20210324007A1 (en) 2021-10-21
JP7035044B2 (ja) 2022-03-14
EP3538542B1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
DK3519420T3 (da) Cykliske dinukleotidforbindelser
EP3502950A4 (en) MULTIPLIER-ACC
DK3405050T3 (da) Børnesikret snusbeholder
EP3440949A4 (en) FLAVOR INHALER
EP3596108A4 (en) TARGETED IMMUNOTOLERANCE
EP3446605A4 (en) HAND VACUUM
EP3720871A4 (en) TARGETED IMMUNOTOLERANCE
EP3515419A4 (en) High mobility group box i mutant
EP3455498A4 (en) Fuel delivery injector
EP3445380C0 (en) BACTERIOTHERAPY
EP3450133A4 (en) Liquid blow molding method
DK3335532T3 (da) Tandharve
DK3402792T3 (da) Quinolin-2-on-derivater
DK3445708T3 (da) Stigbøjle
DK3538542T3 (da) Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin
EP3402021A4 (en) GRAB WIRE
DK3452590T3 (da) Plademagnet
DK3509963T3 (da) Pallecontainer
EP3478921A4 (en) PULL CORD ARRANGEMENT
EP3475155A4 (en) WING SAILING BOAT
DK3528829T3 (da) Bacitracin-alginat-oligomer-konjugater
DK3575238T3 (da) Pallecontainer
EP3399976C0 (en) BENZOTHIAZOLE AMPHOPHILES
EP3473285A4 (en) Injector
DE112017006386A5 (de) Schraubarbeitszylinder